SEC Form 4 · accession 0001144204-17-062254
Aevi Genomic Medicine, Inc. · GNMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew D Bayley
Director
Period of report
Dec 4, 2017
Accepted (ET)
Dec 4, 2017 · 5:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001138776
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Purchase)F1 | $1.25 | Dec 4, 2017 | A | 40,000 | A | — | Dec 4, 2027 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1The option award vests and becomes exercisable in three equal installments (rounded up to the nearest whole share of common stock) on December 4, 2018, December 4, 2019 and December 4, 2020, subject to the reporting person's continued service with the issuer.